Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1
antibody alone or in combination with low-dose decitabine in patients with relapsed or
refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal
cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell
cancer or pancreatic cancer or bile duct cancer.